...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Combo with Enzalutamide in Phase 2 Metastatic Prostate Cancer Clinical Trial and with Pfizer’s PARPi, talazoparib, in Phase 1b/2 Triple Negative Breast Cancer Trial
Donald J. McCaffrey
President and Chief Executive Officer
Mr. McCaffrey is the co-founder, President and CEO of Zenith Capital Corp., a biotechnology investment company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. Zenith was spun out of Resverlogix Corp. (TSX: RVX) in 2013.
Don has over 38 years of corporate management experience including over 18 years in drug discovery & development. Don’s expertise in corporate operations has attracted an international team of experts to the company, including world renowned Key Opinion Leaders in the fields of oncology.
In addition to Zenith, Don serves as President, CEO and Chairman of Resverlogix Corp. (TSX: RVX), a pioneer in the landscape of epigenetics, currently conducting a global Phase 3 clinical trial – BETonMACE – with the most advanced epigenetic drug outside of oncology, apabetalone.
Don’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year three times. He has also arranged support for several non-profit organizations, including: the Libin Cardiovascular Institute of Alberta, Juvenile Diabetes Research Foundation, Sanofi Biogenius Canada (MindFuel), United Way, Mount Royal University Foundation, Alberta Children's Hospital, Edge School Foundation, Education Matters, Calgary Urban Project Society Literacy Program, Movember Foundation, and Enbridge Ride to Conquer Cancer.
Sanjay Lakhotia, Ph.D, MBA
Chief Business Officer
Dr. Lakhotia has over 25 years of experience in corporate development, product development and strategy at leading biotech and pharmaceutical companies. Between 2010 and 2013, he led corporate development at Pathway Therapeutics, a clinical stage cancer and autoimmune company. Prior to Pathway, Dr. Lakhotia was senior director of corporate development at Portola Pharmaceuticals, where his responsibilities included product licensing and program leadership. While at Portola, he contributed to the partnering of a significant Phase 2 asset and championed the development of an important cardiovascular drug now in registration with breakthrough therapy status.
Prior to joining Portola in 2006, Dr. Lakhotia held corporate development positions of increasing responsibilities at Onyx Pharmaceuticals and MedImmune where he led the execution of several product and technology licensing transactions. Before transitioning to corporate development, he led process development groups at Wyeth Pharmaceuticals and Baxter contributing to the development of important vaccines, Prevnar and Meningetec.
Dr. Lakhotia obtained his Ph.D. in Biochemical Engineering at Northwestern University, an MBA from University of North Carolina, Chapel Hill, and BS in chemical engineering from the University of California, Berkeley.
A. Brad Cann, CPA, CA, CBV
Chief Financial Officer
Mr. Cann has more than 20 years of experience in a variety of financial and corporate roles. Prior to joining Resverlogix, Mr. Cann was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust. Previous to his positions with Royal Host, he was a business consultant and held senior management positions with several companies including Chief Financial Officer of Sulphur Corporation of Canada Ltd. Prior thereto, Mr. Cann held various positions with Kenway Mack Slusarchuk Stewart Chartered Accountants.
Brad is a Chartered Professional Accountant and a Chartered Business Valuator, and holds a Bachelor of Commerce from the University of Saskatchewan.
Henrik C. Hansen, Ph.D.
Senior Vice President of Operations
Dr. Hansen has 20 years of experience, from both academia and industry, in basic research, drug discovery, and drug development. His areas of expertise include medicinal chemistry, carbohydrate chemistry, high throughput synthesis, process development, and manufacturing of drug substances and drug products under Good Manufacturing Practices (GMPs) for clinical use.
Dr. Hansen holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 70 articles and meeting abstracts and is listed as an inventor of 12 patent families.
Edward van der Horst, Ph.D.
Vice President of Discovery Research and Preclinical Development
Dr. van der Horst has 17 years of experience working with small molecules, antibodies, and antibody-drug conjugates in the biotechnology industry and has extensive experience in target discovery, selection and validation in the oncology and immuno-oncology space.
Prior to joining Zenith, Dr. van der Horst spearheaded the preclinical drug development efforts at Igenica Biopharmaceuticals Inc. which resulted in the successful acquisition of immuno-oncology assets by Pierre Fabre. Previously, his contributions and discoveries have led to the development and clinical evaluation of various antibodies at OncoMed Pharmaceuticals, as well as to the first clinical stage anti-HER3 antibody at U3 Pharma GmbH (acquired by Daiichi-Sankyo).
Dr. van der Horst conducted his master’s at Max-Planck Institute of Neurobiology and received his Ph.D. in biochemistry from the Max-Planck Institute of Biochemistry. He completed his postdoctoral training at Tularik, Inc.